Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences Plc develops gene therapies for age-related diseases, with company news centered on its SIRT6-based longevity platform and related therapeutic programs. Updates include progress in canine gene therapy work, intellectual property publications for SIRT6 applications, technology collaborations supporting delivery and genomic analysis, and engagement with animal health and biotechnology partners.
Genflow's announcements also cover operating and financial results, warrant exercises and equity issuance, total voting rights, and shareholder approvals for capital authorities. The company trades in London under GENF and on OTCQB under GENFF, and its public updates frequently use UK regulatory news channels for market disclosures.
Genflow Biosciences (LSE:GENF, OTCQB:GENFF) issued a mid-year update for the six months to 30 June 2026, highlighting clinical, partnership, IP and corporate progress for its SIRT6 longevity platform.
The SLAB dog trial reported positive preliminary interim results in February, with all treatment groups showing superior survival versus controls during dosing, no adverse events and a favourable safety and tolerability profile. Three‑month follow-up in April indicated maintained improvements and no adverse events, suggesting early durability; full methylation clock and muscle histology data are due after trial completion at end‑July 2026. The blinded GF‑1004 Dog Aging Study continues, with a six‑month efficacy assessment expected in July 2026.
Genflow entered a fully funded, non‑dilutive LNP collaboration with Acuitas Therapeutics, expanded confidentiality agreements with Tier‑1 animal health companies, and saw publication of an international PCT patent on SIRT6 variants for muscular diseases. The company also advanced glaucoma and broader sarcopenia programmes and appointed Gad Berdugo as Independent Non‑Executive Chairman.
Genflow Biosciences (OTCQB:GENFF) reported that all 13 resolutions at its 29 June 2026 AGM were passed. Ordinary business included receiving 2025 accounts, approving the remuneration report, reappointing PKF Littlejohn as auditor and re-electing all directors.
Shareholders also approved a new share option scheme, authorising directors to allot shares for scheme options up to 14.34% and to allot further shares up to 33%. Special resolutions to disapply statutory pre-emption rights related to these allotment authorities were passed with over 98.7% support.
Genflow Biosciences (OTCQB:GENFF) announced that Independent Non-Executive Chairman Gad Berdugo will attend the BIO International Convention 2026 in San Diego from June 22-25.
He will speak on an RNA therapeutics panel focused on technical advances and clinical validation over the next 3-5 years.
Genflow Biosciences (OTCQB:GENFF, LSE:GENF) will present data from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical study at the Animal Longevity Summit 2026 in Toronto on 1-2 October 2026.
The study evaluates Genflow’s centenarian SIRT6 gene therapy targeting multiple hallmarks of aging in companion animals.
Genflow Biosciences (OTCQB:GENFF, LSE:GENF) will hold its 2026 Annual General Meeting at 11:00 a.m. on 29 June 2026 at One Heddon Street, London.
Board changes: Independent non-executive director Peter King-Lewis is stepping down from the board with immediate effect.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) received notices to exercise warrants for 30,756,577 new ordinary shares, generating gross proceeds of £359,374.99. The issuance comprises 2,631,578 shares at 1.9p and 28,124,999 shares at an adjusted price of 1.1p.
Admission of the Warrant Shares to the FCA Official List and LSE main market is expected on or around 13 May 2026, raising the total issued share capital and voting rights to 566,409,782 shares.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) released final results for the year ended 31 December 2025 and will publish its Annual Report and AGM notice shortly. Key program milestones include a completed dog aging proof-of-concept dosing phase with no adverse events and advancement of MASH (GF-1002) toward clinical readiness with GMP production success and a €4m Wallonia grant reaffirmed.
IP expansion, new commercial CDAs, a pre-IND MSA, and an AI partnership were also disclosed.
Genflow Biosciences (LSE:GENF; OTCQB:GENFF) announced an expansion of confidentiality agreements with additional Tier‑1 global animal health companies on April 28, 2026. The agreements extend third‑party review of data from its canine SIRT6 cent gene therapy programme following positive preliminary interim results reported February 12, 2026.
The interactions are exploratory and the company said it will provide further updates as appropriate.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced a strategic technology collaboration with Acuitas Therapeutics on April 20, 2026. The fully funded, non-dilutive agreement gives Genflow access to Acuitas' lipid nanoparticle (LNP) delivery platform to test its SIRT6 mRNA payload in preclinical studies.
The collaboration covers formulation of Genflow's SIRT6 mRNA by Acuitas, return of LNP formulations for Genflow's preclinical evaluation, and establishes a framework for possible further development subject to preclinical outcomes. The company does not expect near-term revenue impact.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced the international publication of its PCT application WO 2026/062177 A1, covering SIRT6 variants for prevention and treatment of muscular diseases including frailty syndrome and sarcopenia.
The publication broadens Genflow's SIRT6 IP scope internationally, preserves multi-jurisdictional patent filing options, and supports potential development and partnering of its gene therapy platform.